Parmar DV - Search Results

1

Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.

Rastogi A, Dunbar RL, Thacker HP, Bhatt J, Parmar K, Parmar DV. Rastogi A, et al. Among authors: parmar dv. Acta Diabetol. 2020 Jul;57(7):809-818. doi: 10.1007/s00592-020-01487-8. Epub 2020 Feb 6. Acta Diabetol. 2020. PMID: 32030508 Clinical Trial.

2

Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.

Kansagra KA, Parmar D, Jani RH, Srinivas NR, Lickliter J, Patel HV, Parikh DP, Heading H, Patel HB, Gupta RJ, Shah CY, Patel MR, Dholakia VN, Sukhadiya R, Jain MR, Parmar KV, Barot K. Kansagra KA, et al. Clin Pharmacokinet. 2018 Jan;57(1):87-102. doi: 10.1007/s40262-017-0551-3. Clin Pharmacokinet. 2018. PMID: 28508936 Free PMC article. Clinical Trial.

3

Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.

Patel MR, Kansagra KA, Parikh DP, Parmar DV, Patel HB, Soni MM, Patil US, Patel HV, Patel JA, Gujarathi SS, Parmar KV, Srinivas NR. Patel MR, et al. Among authors: parmar dv, parmar kv. Clin Drug Investig. 2018 Jan;38(1):57-65. doi: 10.1007/s40261-017-0584-2. Clin Drug Investig. 2018. PMID: 29022212 Clinical Trial.

4

New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.

Kaul U, Parmar D, Manjunath K, Shah M, Parmar K, Patil KP, Jaiswal A. Kaul U, et al. Cardiovasc Diabetol. 2019 Jun 17;18(1):80. doi: 10.1186/s12933-019-0884-3. Cardiovasc Diabetol. 2019. PMID: 31208414 Free PMC article. Review.

5

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).

Krishnappa M, Patil K, Parmar K, Trivedi P, Mody N, Shah C, Faldu K, Maroo S; PRESS XII study group; Parmar D. Krishnappa M, et al. Cardiovasc Diabetol. 2020 Jun 19;19(1):93. doi: 10.1186/s12933-020-01073-w. Cardiovasc Diabetol. 2020. PMID: 32560724 Free PMC article. Clinical Trial.

6

Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.

Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Gawrieh S, et al. Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19. Hepatology. 2021. PMID: 33811367 Clinical Trial.

7

Limited Sampling Strategy for Accurate Prediction of Pharmacokinetics of Saroglitazar: A 3-point Linear Regression Model Development and Successful Prediction of Human Exposure.

Joshi SN, Srinivas NR, Parmar DV. Joshi SN, et al. Among authors: parmar dv. Clin Ther. 2018 Mar;40(3):456-468.e1. doi: 10.1016/j.clinthera.2018.01.016. Epub 2018 Feb 26. Clin Ther. 2018. PMID: 29496320 Clinical Trial.

8

Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study.

Parmar DV, Kansagra KA, Patel JC, Joshi SN, Sharma NS, Shelat AD, Patel NB, Nakrani VB, Shaikh FA, Patel HV; on behalf of the ZYAN1 Trial Investigators. Parmar DV, et al. Am J Nephrol. 2019;49(6):470-478. doi: 10.1159/000500232. Epub 2019 May 21. Am J Nephrol. 2019. PMID: 31112954 Clinical Trial.

9

A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis.

Siddiqui MS, Idowu MO, Parmar D, Borg BB, Denham D, Loo NM, Lazas D, Younes Z, Sanyal AJ. Siddiqui MS, et al. Clin Gastroenterol Hepatol. 2021 Dec;19(12):2670-2672. doi: 10.1016/j.cgh.2020.10.051. Epub 2020 Nov 2. Clin Gastroenterol Hepatol. 2021. PMID: 33152542 Clinical Trial.

10

Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.

Vuppalanchi R, Caldwell SH, Pyrsopoulos N, deLemos AS, Rossi S, Levy C, Goldberg DS, Mena EA, Sheikh A, Ravinuthala R, Shaikh F, Bainbridge JD, Parmar DV, Chalasani NP. Vuppalanchi R, et al. Among authors: parmar dv. J Hepatol. 2022 Jan;76(1):75-85. doi: 10.1016/j.jhep.2021.08.025. Epub 2021 Sep 4. J Hepatol. 2022. PMID: 34487750 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

47 results

Search Page